<?xml version="1.0" ?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:media="http://search.yahoo.com/mrss/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:seo="http://purl.org/seo/elements/1.0/" version="2.0">
	<channel>
		<title>TMX Newsfile Cannabis Ancillary Service Provider News Releases</title>
		<link>https://feeds.newsfilecorp.com/industry/cannabis-ancillary</link>
		<description>Last 10 Cannabis Ancillary Service Provider news releases from TMX Newsfile. Contact us for a custom full-bodied RSS feed complete with exchange and ticker data.</description>
		<language>en</language>
		<copyright>CopyRight (c) 2026, Newsfile Corp. All Rights Reserved.</copyright>
		<managingEditor>office@newsfilecorp.com (Newsfile Corp.)</managingEditor>
		<webMaster>office@newsfilecorp.com (Newsfile Corp.)</webMaster>
		<lastBuildDate>Tue, 09 Jun 2026 19:32:22 -0400</lastBuildDate>
		<image>
			<url>https://www.newsfilecorp.com/images/tmx-newsfile-wire-logo.png</url>
			<title>TMX Newsfile Cannabis Ancillary Service Provider News Releases</title>
			<link>https://feeds.newsfilecorp.com/industry/cannabis-ancillary</link>
		</image>
		<atom:link rel="self" type="application/rss+xml" href="https://feeds.newsfilecorp.com/industry/cannabis-ancillary"/>
		<item xml:lang="en">
			<title>CORRECTION FROM SOURCE: Entheon Biomedical Corp. Issues Correction to News Release Dated June 9, 2026</title>
			<link>https://www.newsfilecorp.com/release/300836/CORRECTION-FROM-SOURCE-Entheon-Biomedical-Corp.-Issues-Correction-to-News-Release-Dated-June-9-2026</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/300836/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") wishes to correct the effective date of the appointment of Adam Emes as a director of the Company as stated in the Company's news release dated June 9, 2026. The appointment of Mr. Emes to the Company's Board of Directors is effective June 9, 2026, not April 3, 2025 as previously stated. All other information contained in the news release...</description>
			<pubDate>Tue, 09 Jun 2026 19:32:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/300836/CORRECTION-FROM-SOURCE-Entheon-Biomedical-Corp.-Issues-Correction-to-News-Release-Dated-June-9-2026</guid>
		</item>
		<item xml:lang="en">
			<title>Entheon Announces Change of Directors</title>
			<link>https://www.newsfilecorp.com/release/300815/Entheon-Announces-Change-of-Directors</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/300815/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces the appointment of Adam Emes to the Company's Board of Directors, effective April 3, 2025.Mr. Emes is a seasoned entrepreneur with extensive experience in capital markets, corporate development and investor relations. He is the Co-Founder of Black Swan Solutions Inc., where he has worked with over 80 clients across various...</description>
			<pubDate>Tue, 09 Jun 2026 16:26:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/300815/Entheon-Announces-Change-of-Directors</guid>
		</item>
		<item xml:lang="en">
			<title>Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie &amp; Neurosciences in France</title>
			<link>https://www.newsfilecorp.com/release/300482/Red-Light-Hollands-Wholly-Owned-Subsidiary-Filament-Health-Signs-Agreement-to-Supply-PEX010-Botanical-Psilocybin-Drug-Candidate-for-Study-at-GHU-Paris-Psychiatrie-Neurosciences-in-France</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/300482/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;Toronto, Ontario--(Newsfile Corp. - June 8, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived...</description>
			<pubDate>Mon, 08 Jun 2026 07:30:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/300482/Red-Light-Hollands-Wholly-Owned-Subsidiary-Filament-Health-Signs-Agreement-to-Supply-PEX010-Botanical-Psilocybin-Drug-Candidate-for-Study-at-GHU-Paris-Psychiatrie-Neurosciences-in-France</guid>
		</item>
		<item xml:lang="en">
			<title>Red Light Holland Announces Filament Health's PEX010 Drug Candidate, the Standardized and Patented Natural Psilocybin Trusted Across 80+ Studies Globally, Selected by UCSF for Study Probing Preclinical Alzheimer's Markers</title>
			<link>https://www.newsfilecorp.com/release/300117/Red-Light-Holland-Announces-Filament-Healths-PEX010-Drug-Candidate-the-Standardized-and-Patented-Natural-Psilocybin-Trusted-Across-80-Studies-Globally-Selected-by-UCSF-for-Study-Probing-Preclinical-Alzheimers-Markers</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/300117/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;Filament Health will supply its standardized, patented PEX010 botanical psilocybin drug candidate, produced using proprietary extraction and stabilization methods to an independently sponsored UCSF trial examining brain activity, neuroinflammatory markers, and preclinical Alzheimer's disease pathology in healthy older adults.Toronto, Ontario--(Newsfile Corp. - June 4, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an...</description>
			<pubDate>Thu, 04 Jun 2026 07:30:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/300117/Red-Light-Holland-Announces-Filament-Healths-PEX010-Drug-Candidate-the-Standardized-and-Patented-Natural-Psilocybin-Trusted-Across-80-Studies-Globally-Selected-by-UCSF-for-Study-Probing-Preclinical-Alzheimers-Markers</guid>
		</item>
		<item xml:lang="en">
			<title>Entheon Announces Termination of Business Combination Agreement with Nutravisor</title>
			<link>https://www.newsfilecorp.com/release/298801/Entheon-Announces-Termination-of-Business-Combination-Agreement-with-Nutravisor</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/298801/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;Toronto, Ontario--(Newsfile Corp. - May 25, 2026) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that further to its news release dated January 19, 2026, the definitive business combination agreement dated January 19, 2026, as amended on March 9, 2026 (the "Business Combination Agreement") between the Company and Nutravisor Inc. ("Nutravisor"), pursuant to which the parties had agreed to complete a business combination involving a...</description>
			<pubDate>Mon, 25 May 2026 19:21:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/298801/Entheon-Announces-Termination-of-Business-Combination-Agreement-with-Nutravisor</guid>
		</item>
		<item xml:lang="en">
			<title>Red Light Holland Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health's GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate</title>
			<link>https://www.newsfilecorp.com/release/298742/Red-Light-Holland-Expands-New-Zealand-Partnership-with-Allu-Therapeutics-to-Advance-Access-to-Filament-Healths-GMPCompliant-PEX010-Botanical-Psilocybin-Drug-Candidate</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/298742/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;The expanded agreement adds Filament Health, a wholly owned subsidiary of Red Light Holland, as a supplying affiliate and introduces a GMP-compliant standardized microdose format of PEX010 supported by long-term stability and safety data.Toronto, Ontario--(Newsfile Corp. - May 25, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company"), is an Ontario-based organization advancing innovation and research within the legal...</description>
			<pubDate>Mon, 25 May 2026 08:40:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/298742/Red-Light-Holland-Expands-New-Zealand-Partnership-with-Allu-Therapeutics-to-Advance-Access-to-Filament-Healths-GMPCompliant-PEX010-Botanical-Psilocybin-Drug-Candidate</guid>
		</item>
		<item xml:lang="en">
			<title>Britannia Life Sciences Provides Corporate Update</title>
			<link>https://www.newsfilecorp.com/release/298382/Britannia-Life-Sciences-Provides-Corporate-Update</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/298382/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;Toronto, Ontario--(Newsfile Corp. - May 21, 2026) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") today provides a corporate update on its current asset position, strategic direction, and capital markets initiatives. The Board of Directors has approved a refined corporate strategy which repositions Britannia as a public market "venture builder and company accelerator." Separately, the Board has also approved the commencement of a normal course issuer bid (the "NCIB"),...</description>
			<pubDate>Thu, 21 May 2026 09:08:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/298382/Britannia-Life-Sciences-Provides-Corporate-Update</guid>
			<atom:subtitle>Corporate Treasury Positioned with Cash and Liquid Equity Holdings to Seed, Incubate and Accelerate New and Existing Operations</atom:subtitle>
		</item>
		<item xml:lang="en">
			<title>Quinsam Announces Q1/2026 Results</title>
			<link>https://www.newsfilecorp.com/release/297813/Quinsam-Announces-Q12026-Results</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/297813/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION BY ANY UNITED STATES NEWS DISTRIBUTION SERVICEToronto, Ontario--(Newsfile Corp. - May 19, 2026) - Quinsam Capital Corporation (CSE: QCA) ("Quinsam" or the "Company") is announcing its Q1/2026 results, with net income of $1.4 million ($0.015 per share basic, $0.015 fully diluted) versus net income of $0.2 million ($0.002 per share basic, $0.002 fully diluted) in Q1/2025. Investors can access the Company's full financial statements on...</description>
			<pubDate>Tue, 19 May 2026 08:00:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/297813/Quinsam-Announces-Q12026-Results</guid>
		</item>
		<item xml:lang="en">
			<title>Red Light Holland's Wholly Owned Subsidiary, Filament Health, Advances PEX010 Clinical Footprint with New Canadian Academic Studies in Palliative Care, Bipolar II Depression, and Healthy Adult Mechanism Research</title>
			<link>https://www.newsfilecorp.com/release/297469/Red-Light-Hollands-Wholly-Owned-Subsidiary-Filament-Health-Advances-PEX010-Clinical-Footprint-with-New-Canadian-Academic-Studies-in-Palliative-Care-Bipolar-II-Depression-and-Healthy-Adult-Mechanism-Research</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/297469/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;Toronto, Ontario--(Newsfile Corp. - May 14, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development...</description>
			<pubDate>Thu, 14 May 2026 08:30:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/297469/Red-Light-Hollands-Wholly-Owned-Subsidiary-Filament-Health-Advances-PEX010-Clinical-Footprint-with-New-Canadian-Academic-Studies-in-Palliative-Care-Bipolar-II-Depression-and-Healthy-Adult-Mechanism-Research</guid>
		</item>
		<item xml:lang="en">
			<title>Red Light Holland Announces Shareholder Approval of Name Change and Announces Voting Results from 2026 Annual General and Special Meeting of Shareholders</title>
			<link>https://www.newsfilecorp.com/release/297312/Red-Light-Holland-Announces-Shareholder-Approval-of-Name-Change-and-Announces-Voting-Results-from-2026-Annual-General-and-Special-Meeting-of-Shareholders</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/297312/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light Holland" or the "Company") is pleased to announce that shareholders overwhelmingly approved the Company's proposed corporate name change at the Company's annual general and special meeting of shareholders ("Shareholders") held on Monday, May 11, 2026 at the Company's office in Toronto (the "Meeting").The special resolution approving the Company's proposed name change...</description>
			<pubDate>Wed, 13 May 2026 09:12:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/297312/Red-Light-Holland-Announces-Shareholder-Approval-of-Name-Change-and-Announces-Voting-Results-from-2026-Annual-General-and-Special-Meeting-of-Shareholders</guid>
		</item>
	</channel>
</rss>
